Abaloparatide for treating idiopathic or hypogonadal osteoporosis in men [ID4059] | Technology appraisal guidance | TBC |
Abemaciclib with abiraterone acetate and prednisone for treating hormone-relapsed metastatic prostate cancer [ID6230] | Technology appraisal guidance | TBC |
Abemaciclib with fulvestrant for previously treated hormone receptor-positive HER2-negative advanced breast cancer TSID 12065 | Technology appraisal guidance | TBC |
Abicipar pegol for treating wet age-related macular degeneration ID1533 | Technology appraisal guidance | TBC |
Abortion Care | NICE guideline | |
Acalabrutinib and venetoclax with or without obinutuzumab for untreated chronic lymphocytic leukaemia ID6232 | Technology appraisal guidance | TBC |
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155] | Technology appraisal guidance | |
Acoramidis for treating transthyretin-related amyloidosis cardiomyopathy ID6354 | Technology appraisal guidance | TBC |
Adagrasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6339] | Technology appraisal guidance | |
Advanced breast cancer: diagnosis and management (Partial update) | NICE guideline | TBC |
Alpelisib with olaparib for treating BRCA wild-type platinum-refractory or -resistant ovarian, fallopian tube or primary peritoneal cancer after 1 to 3 previous treatments [TSID11830] [ID6247] | Technology appraisal guidance | TBC |
ALXN1840 for treating Wilson disease TS ID 9950 | Technology appraisal guidance | TBC |
Alzheimer's disease (early) - gantenerumab [ID6142] | Technology appraisal guidance | TBC |
Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer [ID5110] | Technology appraisal guidance | |
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256] | Technology appraisal guidance | |
Amyotrophic lateral sclerosis - SAR443820 [ID6386] | Technology appraisal guidance | TBC |
Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215] | Technology appraisal guidance | TBC |
Arimoclomol for treating Niemann-Pick disease Type C [ID1312] | Highly specialised technology | TBC |
Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway: early value assessment | Health technology evaluation | TBC |
Artificial intelligence software to help detect and characterise colorectal polyps | Diagnostics guidance | |
Artificial intelligence technologies to aid the opportunistic detection of vertebral fragility fractures : Early Value Assessment | Health technology evaluation | |
Asunercept for treating glioblastoma [1301] | Technology appraisal guidance | TBC |
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701 | Technology appraisal guidance | TBC |
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200] | Technology appraisal guidance | TBC |
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730] | Technology appraisal guidance | TBC |
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324] | Technology appraisal guidance | |
Atezolizumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6148] | Technology appraisal guidance | TBC |
Atezolizumab with cabozantinib for treating hormone-relapsed metastatic prostate cancer after 1 therapy [ID6203] | Technology appraisal guidance | TBC |
Atezolizumab with chemotherapy for treating relapsing recurrent advanced triple-negative early breast cancer [ID6152] | Technology appraisal guidance | TBC |
Aumolertinib for untreated EGFR mutation-positive non-small-cell lung cancer [ID4000] | Technology appraisal guidance | TBC |
Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707] | Technology appraisal guidance | TBC |
Avelumab for previously treated platinum-resistant ovarian cancer ID1497 | Technology appraisal guidance | TBC |
Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261] | Technology appraisal guidance | TBC |
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294] | Technology appraisal guidance | |
Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour | Interventional procedures guidance | |
Beating heart mitral valve repair by artificial chordae insertion for mitral regurgitation | Interventional procedures guidance | |
Bed frames for adults in acute settings: Late Stage-assessment | Health technology evaluation | |
Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701] | Technology appraisal guidance | TBC |
Belantamab mafodotin with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6212 | Technology appraisal guidance | TBC |
Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211 | Technology appraisal guidance | TBC |
Belzutifan for previously treated advanced renal cell carcinoma [ID6154] | Technology appraisal guidance | TBC |
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266] | Technology appraisal guidance | |
Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959] | Technology appraisal guidance | |
Betula verrucosa (Itulazax 12 SQ-Bet) for treating moderate to severe allergic rhinitis, conjunctivitis, or both, caused by tree pollen ID6462 | Technology appraisal guidance | |
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145] | Technology appraisal guidance | |
BI 907828 for untreated dedifferentiated advanced liposarcoma [ID6296] | Technology appraisal guidance | TBC |
Bimatoprost implant for treating open angle glaucoma or ocular hypertension when topical treatments are unsuitable [ID6180] | Technology appraisal guidance | TBC |
Bipolar disorder: assessment and management (extraordinary review) | NICE guideline | TBC |
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemia [ID6405] | Technology appraisal guidance | |
Botulinum toxin type A for treating upper or lower limb focal spasticity associated with stroke [ID768] | Technology appraisal guidance | TBC |
Breast cancer guidelines | NICE guideline | TBC |
Brentuximab vedotin with doxorubicin, dacarbazine and vinblastine for previously untreated late-stage classical Hodgkin lymphoma (including Review of TA594) [ID6334] | Technology appraisal guidance | TBC |
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325] | Technology appraisal guidance | |
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ] | Technology appraisal guidance | TBC |
Cabotegravir for preventing HIV-1 in adults and young people [ID6255] | Technology appraisal guidance | TBC |
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243] | Technology appraisal guidance | |
Cabozantinib for treating advanced neuroendocrine tumours that have progressed after systemic treatment ID6474 | Technology appraisal guidance | |
Cabozantinib with nivolumab and ipilimumab for untreated intermediate- or poor-risk advanced renal cell carcinoma [ID6330] | Technology appraisal guidance | TBC |
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653] | Technology appraisal guidance | TBC |
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370] | Technology appraisal guidance | |
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383] | Technology appraisal guidance | TBC |
Cardiometabolic disease prevention and treatment guidelines | NICE guideline | TBC |
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639] | Technology appraisal guidance | TBC |
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949] | Technology appraisal guidance | TBC |
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (MA review of HST12) [ID6145] | Highly specialised technology | TBC |
Chronic heart failure in adults: diagnosis and management - Pharmacological treatment of chronic heart failure | NICE guideline | |
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012] | Technology appraisal guidance | TBC |
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259] | Technology appraisal guidance | TBC |
Cladribine for treating relapsing multiple sclerosis [ID6263] | Technology appraisal guidance | |
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398] | Technology appraisal guidance | TBC |
COLOFIT algorithm to guide colorectal cancer pathway referral in primary care: early value assessment | Health technology evaluation | TBC |
Colon cancer (adjuvant) - irinotecan [ID379] | Technology appraisal guidance | TBC |
Compression products for treating venous leg ulcers: late stage assessment | Health technology evaluation | |
Corticosteroid-releasing bioabsorbable stent or spacer insertion during endoscopic sinus surgery to treat chronic rhinosinusitis | Interventional procedures guidance | TBC |
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826] | Technology appraisal guidance | TBC |
Dapagliflozin for treating chronic kidney disease [ID6411] | Technology appraisal guidance | TBC |
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987] | Technology appraisal guidance | TBC |
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated
multiple myeloma when a stem cell transplant is unsuitable ID3843 | Technology appraisal guidance | TBC |
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when an autologous stem cell transplant is suitable ID6249 | Technology appraisal guidance | TBC |
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer ID6452 | Technology appraisal guidance | TBC |
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 | Technology appraisal guidance | TBC |
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297 | Technology appraisal guidance | |
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348] | Technology appraisal guidance | TBC |
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241] | Technology appraisal guidance | TBC |
DCVax-L for treating glioblastoma [ID836] | Technology appraisal guidance | TBC |
Degarelix before or with radiotherapy for treating high-risk localised and locally advanced hormone-dependent prostate cancer [ID6419] | Technology appraisal guidance | TBC |
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years ID3897 | Technology appraisal guidance | TBC |
Delgocitinib for treating moderate to severe chronic hand eczema ID6408 | Technology appraisal guidance | |
Depemokimab for treating severe eosinophilic asthma in people 12 years and over ID6447 | Technology appraisal guidance | TBC |
Dexmedetomidine for treating agitation associated with bipolar disorder in people 18 to 75 years [TS ID 10725] | Technology appraisal guidance | TBC |
Dexmedetomidine for treating agitation associated with schizophrenia TS ID 10726 | Technology appraisal guidance | TBC |
Diabetic retinopathy - ruboxistaurin [ID382] | Technology appraisal guidance | TBC |
Digital front door technologies to pre-assess people before assessment for NHS Talking Therapies : Early Value Assessment | Health technology evaluation | |
Digital platforms to support cardiac rehabilitation: early value assessment | Health technology evaluation | |
Digital support for people with eating disorders: early value assessment | Health technology evaluation | |
Digital technologies for managing mild to moderate hip or knee osteoarthritis: early-value assessment | Health technology evaluation | |
Digital technologies to support smoking cessation in secondary care patients: early value assessment | Health technology evaluation | |
Digital therapy for chronic tic disorders and Tourette syndrome: early value assessment | Health technology evaluation | |
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222] | Technology appraisal guidance | |
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency ID6415 | Technology appraisal guidance | |
Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314] | Technology appraisal guidance | TBC |
Drug-eluting coronary stents for treating coronary artery disease: late-stage assessment | Health technology evaluation | |
Dupilumab for treating chronic spontaneous urticaria in people 12 years and over [ID4055] | Technology appraisal guidance | TBC |
Dupilumab for treating moderate to severe chronic obstructive pulmonary disease ID6235 | Technology appraisal guidance | TBC |
Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480] | Technology appraisal guidance | |
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263] | NICE guideline | TBC |
Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263] | Technology appraisal guidance | TBC |
Durvalumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5073] | Technology appraisal guidance | |
Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer
[ID6490] | Technology appraisal guidance | TBC |
Durvalumab with gemcitabine and cisplatin before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating muscle-invasive bladder cancer [ID6168] | Technology appraisal guidance | TBC |
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for treating newly diagnosed advanced or recurrent endometrial cancer ID6317 | Technology appraisal guidance | |
Durvalumab with tremelimumab for untreated advanced or unresectable hepatocellular carcinoma [ID2725] | Technology appraisal guidance | |
Early and locally advanced breast cancer: diagnosis and management - Neoadjuvant chemotherapy and ovarian function suppression (update) | NICE guideline | |
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170] | Technology appraisal guidance | |
Efgartigimod for treating generalised myasthenia gravis [ID4003] | Technology appraisal guidance | TBC |
Efgartigimod with recombinant human hyaluronidase PH20 for treating chronic inflammatory demyelinating polyneuropathy ID6409 | Technology appraisal guidance | TBC |
Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060] | Technology appraisal guidance | |
Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240] | Technology appraisal guidance | TBC |
Encorafenib with binimetinib for treating BRAF V600E mutation-positive advanced non-small-cell lung cancer [ID6177] | Technology appraisal guidance | |
Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma | Interventional procedures guidance | TBC |
Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845] | Technology appraisal guidance | |
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable [ID6332] | Technology appraisal guidance | |
Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338] | Technology appraisal guidance | TBC |
Epilepsies in children, young people and adults (extraordinary review) | NICE guideline | TBC |
ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623] | Technology appraisal guidance | TBC |
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333] | Technology appraisal guidance | |
Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke TS ID 11920 | Technology appraisal guidance | TBC |
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests | Diagnostics guidance | TBC |
Falls: assessment and prevention in older people and people 50 and over at higher risk (update) | NICE guideline | |
Familial Breast Cancer: initial assessment and genetic testing (update) | NICE guideline | |
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393] | Technology appraisal guidance | TBC |
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over [ID1651] | Technology appraisal guidance | |
Fertility problems: assessment and treatment - update 1 and 2 | NICE guideline | TBC |
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071] | Technology appraisal guidance | |
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032] | Technology appraisal guidance | TBC |
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133] | Technology appraisal guidance | TBC |
Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264] | Highly specialised technology | TBC |
Fruquintinib for previously treated metastatic colorectal cancer ID6274 | Technology appraisal guidance | TBC |
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394] | Technology appraisal guidance | |
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain | Medical technologies guidance | TBC |
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312 | Technology appraisal guidance | TBC |
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323] | Technology appraisal guidance | |
Glaucoma - lerdelimumab (CAT-152) [ID383] | Technology appraisal guidance | TBC |
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202] | Technology appraisal guidance | |
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis ID6487 | Technology appraisal guidance | |
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238 | Technology appraisal guidance | TBC |
Guselkumab for treating moderately to severely active ulcerative colitis ID6237 | Technology appraisal guidance | |
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627] | Technology appraisal guidance | TBC |
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343] | Technology appraisal guidance | TBC |
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251] | Technology appraisal guidance | TBC |
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483] | Technology appraisal guidance | TBC |
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547] | Technology appraisal guidance | TBC |
Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922] | Technology appraisal guidance | TBC |
Imlunestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer after endocrine therapy [ID6373] | Technology appraisal guidance | TBC |
Implanting a baroreceptor stimulation device for resistant hypertension | Interventional procedures guidance | TBC |
Inavolisib with palbociclib and fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-positive advanced breast cancer after adjuvant endocrine treatment [ID6425] | Technology appraisal guidance | TBC |
Infigratinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 fusion or rearrangement [ID3992] | Technology appraisal guidance | TBC |
Inhaled treprostinil for treating pulmonary hypertension with interstitial lung disease ID6459 | Technology appraisal guidance | |
Insulin icodec for treating type 2 diabetes [ID6175] | Technology appraisal guidance | TBC |
Intermittent urethral catheters for chronic incomplete bladder emptying in adults: late-stage assessment | Health technology evaluation | |
Intrapartum Care - maternal hyponatremia | NICE guideline | |
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355] | Technology appraisal guidance | TBC |
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889] | Technology appraisal guidance | TBC |
Iptacopan for treating complement 3 glomerulopathy [ID6283] | Technology appraisal guidance | |
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitable ID3981 | Technology appraisal guidance | |
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067] | Technology appraisal guidance | |
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517] | Technology appraisal guidance | TBC |
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706] | Technology appraisal guidance | TBC |
Kidney Cancer | NICE guideline | TBC |
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687] | Technology appraisal guidance | TBC |
Laparoscopic insertion of an inactive implant for gastro-oesophageal reflux disease | Interventional procedures guidance | |
Leadless cardiac pacemaker implantation for bradyarrhythmias | Interventional procedures guidance | |
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043] | Technology appraisal guidance | |
Lenacapavir for preventing HIV-1 in people aged 16 years or older ID6495 | Technology appraisal guidance | TBC |
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410] | Technology appraisal guidance | TBC |
Leniolisib for activated phosphoinositide 3-kinase delta syndrome in people 12 years and over [ID6130] | Highly specialised technology | |
Leriglitazone for treating andrenoleukodystrophy [ID3903] | Technology appraisal guidance | TBC |
Letermovir for preventing cytomegalovirus infection after a kidney transplant [ID6166] | Technology appraisal guidance | TBC |
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390] | Technology appraisal guidance | TBC |
Lifileucel for previously treated unresectable or metastatic melanoma ID3863 | Technology appraisal guidance | |
Linzagolix for treating symptoms of endometriosis [ID6357] | Technology appraisal guidance | |
Lisocabtagene maraleucel for treating relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6174] | Technology appraisal guidance | TBC |
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitable [ID3887] | Technology appraisal guidance | |
Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer (Review of TA909) [ID6434] | Technology appraisal guidance | |
Low energy contact X-ray brachytherapy (the Papillon technique) for rectal cancer | Interventional procedures guidance | |
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517] | Technology appraisal guidance | TBC |
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44] | Technology appraisal guidance | TBC |
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43] | Technology appraisal guidance | TBC |
Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340 | Technology appraisal guidance | TBC |
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872] | Technology appraisal guidance | TBC |
Managing common infections - antimicrobial prescribing guidelines | NICE guideline | TBC |
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941] | Technology appraisal guidance | TBC |
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818] | Technology appraisal guidance | TBC |
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342] | Technology appraisal guidance | |
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257] | Technology appraisal guidance | TBC |
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy
[ID6523] | Technology appraisal guidance | TBC |
Melanoma (metastatic) - talimogene laherparepvec [ID508] | Technology appraisal guidance | |
Mental health guidelines | NICE guideline | TBC |
Mirikizumab for treating moderately to severely active Crohn's disease [ID6244] | Technology appraisal guidance | TBC |
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527] | Technology appraisal guidance | TBC |
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442] | Technology appraisal guidance | |
Molnupiravir for treating COVID 19 [ID6340] | Technology appraisal guidance | |
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695] | Technology appraisal guidance | TBC |
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369] | Technology appraisal guidance | |
Navitoclax with ruxolitinib for treating myelofibrosis when stem cell transplant is unsuitable [ID5096] | Technology appraisal guidance | TBC |
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over ID6221 | Technology appraisal guidance | |
Nemolizumab for treating prurigo nodularis [ID6451] | Technology appraisal guidance | |
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858] | Technology appraisal guidance | |
Nintedanib for treating fibrosing interstitial lung disease in people aged 6 to 17 [ID6194] | Technology appraisal guidance | TBC |
Nitazoxanide for treating the common cold in people 12 years and over [ID4049] | Technology appraisal guidance | TBC |
Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310] | Technology appraisal guidance | |
Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858] | Technology appraisal guidance | |
Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053] | Technology appraisal guidance | TBC |
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102] | Technology appraisal guidance | TBC |
Nivolumab with ipilimumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136] | Technology appraisal guidance | TBC |
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939] | Technology appraisal guidance | TBC |
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248] | Technology appraisal guidance | TBC |
Non-alcoholic fatty liver disease (NAFLD): assessment and management | NICE guideline | TBC |
Non-invasive skin closure devices for surgical incisions (MT775) | Medical technologies guidance | TBC |
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195] | Technology appraisal guidance | |
NY-ESO-1 T-cells for treating synovial sarcoma ID1286 | Technology appraisal guidance | TBC |
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347] | Technology appraisal guidance | |
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645] | Technology appraisal guidance | TBC |
Obinutuzumab for treating lupus nephritis ID6420 | Technology appraisal guidance | TBC |
Obsessive-compulsive and related disorders: assessment and management | NICE guideline | TBC |
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181] | Technology appraisal guidance | TBC |
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ] | Highly specialised technology | |
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423 | Technology appraisal guidance | |
Omburtamab for treating relapsed neuroblastoma [ID1664] | Technology appraisal guidance | TBC |
One-piece closed bags for colostomies: Late Stage Assessment | Health technology evaluation | |
Optical Coherence Tomography to guide percutaneous coronary intervention | Interventional procedures guidance | TBC |
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111] | Technology appraisal guidance | TBC |
OrganOx metra for liver transplant [ID5116] | Technology appraisal guidance | TBC |
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223] | Technology appraisal guidance | |
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328] | Technology appraisal guidance | TBC |
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update) | NICE guideline | TBC |
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089] | Technology appraisal guidance | TBC |
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251] | Technology appraisal guidance | TBC |
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144] | Technology appraisal guidance | TBC |
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380] | Technology appraisal guidance | |
Peezy Midstream for urine collection (MT446) | Medical technologies guidance | TBC |
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594 | Technology appraisal guidance | TBC |
Pegcetacoplan for treating geographic atrophy [ID4041] | Technology appraisal guidance | TBC |
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461] | Technology appraisal guidance | TBC |
Pegzilarginase for treating arginase-1 deficiency [ID4029] | Highly specialised technology | TBC |
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473 | Technology appraisal guidance | TBC |
Pembrolizumab with carboplatin and paclitaxel for untreated advanced or recurrent endometrial cancer [ID6381] | Technology appraisal guidance | TBC |
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138] | Technology appraisal guidance | |
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207] | Technology appraisal guidance | TBC |
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363] | Technology appraisal guidance | TBC |
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861] | Technology appraisal guidance | TBC |
Pembrolizumab with lenvatinib and chemotherapy for untreated advanced gastro-oesophageal junction cancer [TSID11861] | Technology appraisal guidance | TBC |
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028] | Technology appraisal guidance | TBC |
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814] | Technology appraisal guidance | TBC |
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044] | Technology appraisal guidance | TBC |
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149] | Technology appraisal guidance | TBC |
Pembrolizumab–vibostolimab for untreated metastatic non-small-cell lung cancer [ID6365] | Technology appraisal guidance | TBC |
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361] | Technology appraisal guidance | TBC |
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172] | Technology appraisal guidance | TBC |
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724] | Technology appraisal guidance | TBC |
PillCam COLON 2 for investigation of the colon through direct visualisation | Diagnostics guidance | |
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269] | Technology appraisal guidance | TBC |
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975] | Technology appraisal guidance | TBC |
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397] | Technology appraisal guidance | TBC |
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353 | Technology appraisal guidance | TBC |
Pneumonia: diagnosis and management (update) | NICE guideline | |
Polihexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497] | Technology appraisal guidance | TBC |
Polycystic ovary syndrome: diagnosis and management | NICE guideline | TBC |
Port Delivery platform with ranibizumab for treating wet age-related macular degeneration [ID3983] | Technology appraisal guidance | TBC |
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure | Diagnostics guidance | |
Pulsed field ablation for atrial fibrillation | Interventional procedures guidance | |
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056] | Technology appraisal guidance | |
Rehabilitation for chronic neurological disorders including acquired brain injury | NICE guideline | |
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982] | Technology appraisal guidance | |
Renal cell carcinoma Pathways Pilot [ID6186] | Technology appraisal guidance | TBC |
Repotrectinib for treating NTRK fusion-positive advanced solid tumours in people 12 years and over [TSID12147] | Technology appraisal guidance | TBC |
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277] | Technology appraisal guidance | TBC |
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007 | Technology appraisal guidance | TBC |
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307) | Technology appraisal guidance | TBC |
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153] | Technology appraisal guidance | |
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601] | Technology appraisal guidance | TBC |
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496] | Technology appraisal guidance | TBC |
Robot-assisted surgery for orthopaedic procedures: early value assessment | Health technology evaluation | TBC |
Robot-assisted surgery for soft-tissue procedures: early value assessment | Health technology evaluation | TBC |
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596] | Technology appraisal guidance | TBC |
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092] | Technology appraisal guidance | TBC |
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [ID5100] | Technology appraisal guidance | |
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377] | Technology appraisal guidance | |
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427] | Technology appraisal guidance | TBC |
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998] | Technology appraisal guidance | TBC |
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375] | Technology appraisal guidance | TBC |
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033] | Technology appraisal guidance | TBC |
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150] | Technology appraisal guidance | TBC |
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284] | Technology appraisal guidance | |
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738] | Technology appraisal guidance | TBC |
Seladelpar for previously treated primary biliary cholangitis ID6429 | Technology appraisal guidance | |
Selpercatinib for treating RET fusion-positive advanced solid tumours in people aged 12 and over with no other treatment options [ID6273] | Technology appraisal guidance | TBC |
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183] | Technology appraisal guidance | TBC |
Semaglutide for managing overweight and obesity and the reduction of associated cardiovascular risk (ID6441 including a review of TA875 and TA910) | Technology appraisal guidance | TBC |
Serplulimab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer [ID6346] | Technology appraisal guidance | |
Sipavibart for preventing COVID 19 [ID6282] | Technology appraisal guidance | TBC |
Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440] | Technology appraisal guidance | |
Slide sheets for repositioning or moving a person: late stage assessment | Health technology evaluation | |
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246] | Technology appraisal guidance | TBC |
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439] | Technology appraisal guidance | TBC |
Somapacitan for treating growth hormone deficiency in children [ID6178] | Technology appraisal guidance | TBC |
Sotatercept for treating pulmonary arterial hypertension [ID6163] | Technology appraisal guidance | |
Soticlestat for treating seizures associated with Dravet syndrome in people 2 years and over TSID 12091 | Technology appraisal guidance | TBC |
Soticlestat for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and over TSID 10632 | Technology appraisal guidance | TBC |
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287] | Technology appraisal guidance | TBC |
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals) | Medical technologies guidance | TBC |
Sparsentan for treating primary IgA nephropathy [ID6308] | Technology appraisal guidance | |
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668] | Technology appraisal guidance | |
Spesolimab for preventing generalised pustular psoriasis flares [ID6216] | Technology appraisal guidance | TBC |
Spesolimab for treating generalised pustular psoriasis flares [ID3963] | Technology appraisal guidance | TBC |
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001] | Technology appraisal guidance | TBC |
Surgical vessel sealing systems (MT798) | Medical technologies guidance | TBC |
Suspected sepsis: recognition, diagnosis and early management | NICE guideline | TBC |
Suspected sepsis: recognition, diagnosis and early management | NICE guideline | |
Talacotuzumab for untreated acute myeloid leukaemia [ID1262] | Technology appraisal guidance | TBC |
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004] | Technology appraisal guidance | |
Talquetamab for treating relapsed or refractory multiple myeloma after 3 treatments [ID5082] | Technology appraisal guidance | |
Targeted muscle reinnervation for managing limb amputation pain | Interventional procedures guidance | |
Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485] | Technology appraisal guidance | |
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364] | Technology appraisal guidance | |
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401 | Technology appraisal guidance | TBC |
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253] | Technology appraisal guidance | TBC |
Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes [ID6259] | Technology appraisal guidance | |
Teprotumumab for treating thyroid eye disease [ID6432] | Technology appraisal guidance | |
Third molars (impacted) - prophylactic removal [ID898] | Technology appraisal guidance | TBC |
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy ID6161 | Technology appraisal guidance | TBC |
Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy [ID4070] | Technology appraisal guidance | TBC |
Tislelizumab in combination for untreated advanced non-small-cell lung cancer ID6162 | Technology appraisal guidance | TBC |
Tislelizumab with chemotherapy for untreated advanced oesophageal squamous cell cancer ID5113 | Technology appraisal guidance | TBC |
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753] | Technology appraisal guidance | TBC |
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767] | Highly specialised technology | TBC |
Topical antimicrobial dressings for infected leg ulcers in people aged 16 and over: Late stage assessment | Health technology evaluation | |
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391] | Technology appraisal guidance | TBC |
Total hip arthroplasty using the superpath approach for osteoarthritis | Interventional procedures guidance | TBC |
Transcatheter aortic valve implantation for native aortic valve regurgitation | Interventional procedures guidance | |
Transcatheter heart valves for transcatheter aortic valve implantation to treat aortic stenosis: Late stage assessment | Health technology evaluation | TBC |
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments [ID6309] | Technology appraisal guidance | |
Treatments for non-small-cell lung cancer [ID6234] | Technology appraisal guidance | TBC |
Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [ID6165] | Technology appraisal guidance | TBC |
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227] | Technology appraisal guidance | TBC |
Type 2 diabetes in adults: management (medicines update) | NICE guideline | |
Upadacitinib for treating giant cell arteritis [ID6299] | Technology appraisal guidance | |
Vanzacaftor–tezacaftor–deutivacaftor for treating cystic fibrosis with 1 or more F508del mutations in the CFTR gene in people aged 6 years and over [ID6372] | Technology appraisal guidance | |
Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277] | Technology appraisal guidance | TBC |
Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314] | Technology appraisal guidance | TBC |
Venetoclax with dexamethasone for treating relapsed or refractory t(11;14)-positive multiple myeloma after lenalidomide and a proteasome inhibitor [ID4040] | Technology appraisal guidance | TBC |
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR (fludarabine, cyclophosphamide, rituximab) or BR (bendamustine, rituximab) are suitable [ID6291] | Technology appraisal guidance | TBC |
Venglustat for treating gangliosidoses in people 2 years and over ID 6358 | Technology appraisal guidance | TBC |
Venoarterial extracorporeal membrane oxygenation (VA ECMO) for acute heart failure in adults | Interventional procedures guidance | |
Venoarterial Extracorporeal membrane oxygenation (VA ECMO) for extracorporeal cardiopulmonary resuscitation (ECPR) in adults in refractory cardiac arrest | Interventional procedures guidance | |
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360] | Technology appraisal guidance | TBC |
Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382] | Technology appraisal guidance | TBC |
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable TSID 12099 | Technology appraisal guidance | TBC |
Violence and aggression: prevention and management | NICE guideline | TBC |
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425] | Technology appraisal guidance | TBC |
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407] | Technology appraisal guidance | |
Vosoritide for treating achondroplasia in people 4 months and over ID6488 | Technology appraisal guidance | TBC |
VTS-270 for treating Niemann-Pick type C1 [ID1267] | Highly specialised technology | TBC |
Vutrisiran for treating transthyretin-related amyloidosis cardiomyopathy [ID6470] | Technology appraisal guidance | |
Waldenstrom's macroglobulinaemia - ibrutinib [ID884] | Technology appraisal guidance | |
Women's and reproductive health guidelines | NICE guideline | TBC |
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199] | Technology appraisal guidance | TBC |
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments ID6388 | Technology appraisal guidance | TBC |
Zanubrutinib for treating relapsed or refractory mantle cell lymphoma after 1 or more treatments [ID6392] | Technology appraisal guidance | |
Zanubrutinib for untreated chronic lymphocytic leukaemia [ID5079] | Technology appraisal guidance | TBC |
Zilucoplan for treating antibody positive generalised myasthenia gravis [ID4008] | Technology appraisal guidance | TBC |
Zio XT for detecting cardiac arrhythmias | Medical technologies guidance | TBC |
Zolbetuximab with chemotherapy for untreated claudin 18.2-positive HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma [ID5123] | Technology appraisal guidance | |
Zuranolone for treating postnatal depression [ID6431] | Technology appraisal guidance | |
Venoarterial Extracorporeal membrane oxygenation (VA ECMO) for postcardiotomy cardiogenic shock in adults | Interventional procedures guidance | TBC |